Effects of an Interactive ICT-Platform for Assessment and Management of Symptoms in Patients Treated for Prostate Cancer (PhONEME)

August 29, 2018 updated by: Ann Langius-Eklöf, Karolinska Institutet

PhONEME - PartipatOn Ehealth MobilE. Effects of an Interactive Information and Communications Technology (ICT) Platform for Assessment and Management of Symptoms in Patients Treated for Prostate Cancer

The purpose of this study is to evaluate the effects of an interactive ICT-platform for use in a smartphone or tablet in patients treated with radiotherapy for prostate cancer. The hypothesis is that clinical management will be improved and costs reduced and safe and participatory care promoted, when patients report symptoms in an application which provides self-care advice and instant access to professionals.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

150

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Sweden
      • Stockholm, Sweden, 17176
        • Karolinska University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Diagnosis of prostate cancer without metastases or spread to the lymph nodes,
  • will receive radiation therapy for at least five (5) weeks,
  • literacy in the Swedish language

Exclusion Criteria:

  • Patients who need an interpreter at the doctor's visit
  • Patients who have a known severe cognitive impairment

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: SUPPORTIVE_CARE
  • Allocation: RANDOMIZED
  • Interventional Model: SINGLE_GROUP
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Intervention group
In combination with usual care according to the routines at the clinic, patients in the intervention group are given access to an application for a smartphone/tablet for daily reporting of symptoms, access to self-care advice and health-care professionals in real time.
Device: smartphone or tablet
Patients in the intervention group are given access to an application for a smartphone/tablet for daily reporting of symptoms, access to self-care advice and health-care professionals in real time.
Other Names:
  • Intervention
NO_INTERVENTION: Control group
Usual care according to the routines at the clinic.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Questionnaire Scale for Functional Health Literacy (S-FHL - Swedish version)
Time Frame: up to 3 months after completion of radiotherapy treatment
To evaluate self-reported data in terms of understanding and communicating health
up to 3 months after completion of radiotherapy treatment
Questionnaire Individualized Care Scale (ICS)
Time Frame: up to 3 months after completion of radiotherapy treatment
To evaluate self-reported data in terms of individualized care as measured by the ICS
up to 3 months after completion of radiotherapy treatment
Questionnaire Sense of Coherence Scale (KASAM)
Time Frame: up to 3 months after completion of radiotherapy treatment
To evaluate self-reported data in terms of Sense of Coherence
up to 3 months after completion of radiotherapy treatment
European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30)
Time Frame: up to 3 months after completion of radiotherapy treatment
To evaluate self-reported data in terms of health related quality of life
up to 3 months after completion of radiotherapy treatment
EORTC Prostate-specific module (QLQ-PR25) Questionnaire
Time Frame: up to 3 months after completion of radiotherapy treatment
To evaluate self-reported data in terms of symptom prevalence, characteristics and distress related to prostate cancer
up to 3 months after completion of radiotherapy treatment
Scale for Communicative and Critical Health Literacy (S-C & C HL - Swedish version)
Time Frame: up to 3 months after completion of radiotherapy treatment
To evaluate self-reported data in terms of health literacy
up to 3 months after completion of radiotherapy treatment

Secondary Outcome Measures

Outcome Measure
Time Frame
Health care costs
Time Frame: up to 3 months after completion of radiotherapy treatment
up to 3 months after completion of radiotherapy treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Karolinska Institutet

Collaborators

Karolinska University Hospital

Investigators

  • Principal Investigator: Ann Langius-Eklöf, RN, PhD, Karolinska Institutet

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

July 20, 2015

Primary Completion (ACTUAL)

March 1, 2018

Study Completion (ACTUAL)

March 7, 2018

Study Registration Dates

First Submitted

June 12, 2015

First Submitted That Met QC Criteria

June 19, 2015

First Posted (ESTIMATE)

June 22, 2015

Study Record Updates

Last Update Posted (ACTUAL)

August 31, 2018

Last Update Submitted That Met QC Criteria

August 29, 2018

Last Verified

August 1, 2018

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • PhONEME Prostate

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Prostate Cancer

Clinical Trials on smartphone or tablet

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritius

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe